welcome
The Motley Fool

The Motley Fool

Health

Health

Incyte stock is tanking after a less-than-encouraging clinical trial results

The Motley Fool
Summary
Nutrition label

64% Informative

Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa.

The biotech's share price was down by nearly 11% week to date as of Friday .

VR Score

53

Informative language

50

Neutral language

8

Article tone

semi-formal

Language

English

Language complexity

54

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

2

Affiliate links

no affiliate links